Henlius 2023 Annual Results Presentation

Henlius reported 2023 revenue of RMB 5.39 billion with net profit of RMB 546 million, driven by strong sales of PD-1 inhibitor HLX10 and trastuzumab HLX02 in China. The biopharmaceutical company achieved strategic licensing deals for HLX10 across Europe and MENA regions, expanded manufacturing capabilities with EU GMP certifications, and advanced its pipeline including novel ADC candidates HLX42 and HLX43.